✦ LIBER ✦

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

✍ Scribed by Judson, Ian; Verweij, Jaap; Gelderblom, Hans; Hartmann, Jörg T; Schöffski, Patrick; Blay, Jean-Yves; Kerst, J Martijn; Sufliarsky, Josef; Whelan, Jeremy; Hohenberger, Peter; Krarup-Hansen, Anders; Alcindor, Thierry; Marreaud, Sandrine; Litière, Saskia; Hermans, Catherine; Fisher, Cyril; Hogendoorn, Pancras C W; dei Tos, A Paolo; van der Graaf, Winette T A

Book ID: 122667854
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 320 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70063-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomised phase II trial of pegylated l

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

✍ I Judson; J.A Radford; M Harris; J.-Y Blay; Q van Hoesel; A le Cesne; A.T van Oo 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 150 KB

First-line treatment of metastatic or lo

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

✍ George D. Demetri; Axel Le Cesne; Sant P. Chawla; Thomas Brodowicz; Robert G. Ma 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 818 KB

Brostallicin versus doxorubicin as first

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

✍ Gelderblom, H.; Blay, J.Y.; Seddon, B.M.; Leahy, M.; Ray-Coquard, I.; Sleijfer, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 758 KB